SMARCB1 and cancer: In comparison to SMARCB1-deficient AT/RT, SMARCA4-mutated AT/RT is associated with a worse prognosis and a higher frequency of inherited germline alterations.5 This worsens prognosis by predisposing patients to early-onset cancers, disrupting cell-cycle regulation, and fueling the tumor’s aggressive nature.